Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma

Inclusion Criteria:

* Histologically documented metastatic or unresectable locally recurrent clear cell renal carcinoma.
* In patients with mixed histologies, the clear cell component must comprise ≥ 75% of the cancer
* Previous nephrectomy is required with the following exceptions:
* Primary tumor \< 5cm
* Extensive liver ( \> 30% of liver parenchyma)or
* Multiple (\> 5) bone metastases, making nephrectomy a clinically contraindicated procedure
* Patients may have had a maximum of 1 previous systemic regimen for metastatic disease
* Patients may not have received previous bevacizumab. However, patients who have received other agents with anti-angiogenic activity (eg. sorafenib, SU11248, AG-013736, PTK787, thalidomide) as part of first-line treatment are eligible
* Patients may not have received previous treatment with m-TOR inhibitors.
* ECOG performance status 0 or 1
* Measurable disease
* Adequate liver, kidney and bone marrow function
* No previous systemic treatment or radiation therapy for at least 2 weeks prior to study entry
* Patients must be able to understand the nature of this study and give written informed consent

Exclusion Criteria:

* Age \< 18 years
* Treatment with \> 1 previous systemic regimen for metastatic renal carcinoma
* History of acute myocardial infarction within 6 months
* Clinically significant cardiovascular disease
* History of stroke within 6 months
* Patients with active brain metastases
* Patients with meningeal metastases
* Women who are pregnant or lactating
* Patients who have been treated within 5 years for other invasive cancers
* Patients with history or evidence by physical examination of CNS disease
* Patients with clinical history of hemoptysis or hematemesis
* Patients with history of deep vein thrombosis or thromboembolic disease requiring full dose anticoagulation
* Patients with major surgical procedures, open biopsies, or significant traumatic injuries within 28 days or anticipated need for major surgical procedure during the course of the study
* Patients with peg-tubes or G-tubes
* Patients are ineligible if a fine needle aspiration biopsy has been performed within seven days
* Patients with proteinuria
* Patients with any non-healing wound, ulcer, or long-bone fracture
* Patients with any history of a bleeding diathesis or coagulopathy
* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months
* Patients who have received any other experimental drug within 28 days of starting treatment
* History of any other severe and/or uncontrolled medical disease
* History of HIV infection
* Chronic treatment with steroids or other immunosuppressive agents
* Patients with impaired GI function that compromises the ability to swallow or absorb RAD001
* Patients who are unwilling or unable to comply with the protocol